Living with chronic inflammatory diseases like rheumatoid arthritis, Crohn’s disease, or psoriasis can make everyday life unpredictable. The pain, swelling, and fatigue can affect everything from mobility to emotional well-being. Abrilada (adalimumab-afzb) is a medication designed to help control these immune-related conditions, offering relief and improving quality of life for many people. 

Abrilada is a biosimilar to Humira (adalimumab), one of the most widely used biologic drugs in the world. It belongs to a class of medications known as tumor necrosis factor (TNF) blockers, which work by targeting a key protein in the body’s immune system that causes inflammation. Approved by the U.S. Food and Drug Administration (FDA) in 2019 and launched in 2023, Abrilada provides patients with a more affordable alternative to Humira while maintaining the same safety, efficacy, and quality standards. 

As a long-term maintenance therapy, Abrilada helps patients gain better control of chronic inflammatory diseases that have not responded well to traditional treatments, helping restore comfort and stability to daily life. 

What does Abrilada do? 

Abrilada is used to reduce inflammation and prevent the immune system from attacking healthy tissues. It treats several autoimmune and inflammatory diseases, including: 

• Rheumatoid arthritis (RA): easing joint pain, swelling, and stiffness 
   

• Psoriatic arthritis: improving joint mobility and skin symptoms 
   

• Ankylosing spondylitis: relieving back pain and improving spinal flexibility 
   

• Crohn’s disease and ulcerative colitis: reducing abdominal pain, diarrhea, and inflammation in the digestive tract 
   

• Plaque psoriasis: decreasing thick, scaly patches of skin 
   

• Juvenile idiopathic arthritis: helping children with autoimmune joint inflammation 

Patients who take Abrilada often report less pain, reduced inflammation, and improved physical function over time. Clinical studies have demonstrated that Abrilada delivers comparable results to Humira, meaning it performs just as effectively in managing disease symptoms and preventing progression (FDA, 2023). 

For many, this medication helps restore mobility, reduces fatigue, and allows them to reengage with daily activities that once felt impossible. 

How does Abrilada work? 

Abrilada contains adalimumab-afzb, a monoclonal antibody that specifically targets tumor necrosis factor-alpha (TNF-α), a naturally occurring protein in the immune system. In people with autoimmune diseases, TNF-α is overproduced, triggering inflammation that damages joints, skin, and other tissues. 

By binding to TNF-α, Abrilada blocks its inflammatory action, preventing it from attaching to its receptors and activating the immune response. This reduces swelling, pain, and tissue damage throughout the body. 

In simple terms, Abrilada helps “calm down” an overactive immune system. Clinically, this mechanism is vital because it not only relieves symptoms but also helps slow or stop long-term joint and tissue damage, preserving mobility and function. 

The drug does not act as a general immune suppressant; rather, it targets a specific pathway, allowing the immune system to continue protecting the body against infections while minimizing harmful inflammation. 

Abrilada side effects 

As with all biologic therapies, Abrilada can cause side effects, though many are mild and manageable. It’s important to recognize what’s typical and when to contact a healthcare provider. 

Common side effects may include: 

• Mild pain, redness, or swelling at the injection site 
   

• Headache or fatigue 
   

• Upper respiratory infections (such as colds or sinus infections) 
   

• Nausea 

Serious side effects (less common): 

• Signs of infection such as fever, persistent cough, or shortness of breath 
   

• Nervous system problems, including vision changes or numbness 
   

• Heart failure symptoms (shortness of breath, swelling in legs) 
   

• Blood disorders (unusual bruising or bleeding) 
   

• Allergic reactions, including rash or facial swelling 

Abrilada impacts the immune system, increasing infection risk (TB, fungal, viral). Patients are screened for TB and hepatitis B before treatment.  

Avoid Abrilada with active infections, severe heart failure, or adalimumab allergies. Discuss risks with a doctor if you have a history of cancer, demyelinating disease, or chronic infections.  

Seek immediate medical attention for severe rash, breathing issues, or persistent fever. Regular doctor visits help manage side effects. 

Abrilada dosage 

Abrilada is a subcutaneous injection, usually given every two weeks, though the schedule varies by condition. It comes in a pre-filled syringe or autoinjector for convenient self-administration at home, typically in the abdomen or thigh, rotating sites to prevent irritation. 

Doctors might suggest regular blood tests to check liver function, blood counts, and infection markers, ensuring the medication’s continued effectiveness and safety. Abrilada is generally safe for older adults and those with chronic liver or kidney disease, though closer monitoring may be necessary. Patients should continue their medication as prescribed, even if symptoms improve, to prevent inflammation from returning. 

Does Abrilada have a generic version? 

Abrilada is a biosimilar, which means it is a highly similar version of a biologic drug, in this case, Humira. Biosimilars are not considered traditional generics because they are made from living cells, but they are equally effective, safe, and high-quality as their reference biologic. 

The FDA has approved Abrilada as a biosimilar to Humira, confirming no meaningful clinical differences in safety, purity, or potency. It is approved for all the same medical indications as Humira. While there’s no generic Abrilada, other Humira biosimilars like Amjevita and Hyrimoz are available, providing affordable alternatives with similar benefits and ensuring the same results as Humira in symptom relief, safety, and quality. 

Conclusion 

Abrilada (adalimumab-afzb) represents a significant advancement in access to biologic therapy for people living with chronic inflammatory and autoimmune diseases. By precisely targeting the body’s TNF-α pathway, it helps control inflammation, reduce pain, and prevent long-term damage, all while improving daily function and quality of life. 

An FDA-approved biosimilar to Humira, Abrilada offers a trusted, cost-effective alternative with the same therapeutic benefits. Side effects are possible but generally manageable with monitoring and communication with a healthcare team. Consistent use and medical supervision can help patients achieve stability, comfort, and confidence, making long-term disease management more hopeful. 

References 

1. U.S. Food and Drug Administration (FDA). (2023). Abrilada (adalimumab-afzb) prescribing information. Retrieved from https://www.accessdata.fda.gov 
    

2. Mayo Clinic. (2024). Adalimumab (injection route) description and precautions. Retrieved from https://www.mayoclinic.org 
    

3. MedlinePlus. (2024). Adalimumab injection: Drug information. National Library of Medicine. Retrieved from https://medlineplus.gov 
    

4. National Institutes of Health (NIH). (2024). TNF inhibitors and autoimmune disease management. Retrieved from https://www.nih.gov